Diagnosis of latent strongyloidiasis following Corticosteroid Therapy in a Patient with COVID-19 infection

Document Type : Case Study

Authors

1 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

2 Department of Medical Parasitology and Mycology, School of Medicine, Zanjan University of Medical Science

3 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

10.32592/ARI.2025.80.2.639

Abstract

Strongyloidiasis, classified as a neglected tropical disease (NTD), is predominantly prevalent in tropical and subtropical areas, impacting an estimated 100-370 million individuals globally. The northern and southern provinces of Iran are recognized as endemic areas for this disease, characterized by environmental conditions such as optimal temperature and humidity conducive to the survival of the causative agent. Although this disease commonly presents no symptoms, individuals with compromised immune systems or those undergoing corticosteroid treatment face an elevated risk of developing hyperinfection syndrome, a serious complication with potentially fatal outcomes. In the case of immunocompromised patients, especially those receiving corticosteroid therapy, the timely diagnosis of strongyloidiasis is imperative as the infection can lead to life-threatening outcomes. This study reports a case of latent strongyloidiasis diagnosis using a serological method. A 68-year-old woman, originally from Guilan Province, living in Tehran Province, with a history of asthma for over a decade, was hospitalized and received corticosteroid treatment for COVID-19. She exhibited symptoms such as shortness of breath, constipation, skin itching, and abdominal bloating. Upon referral to the Diagnostic Laboratory of Strongyloidiasis at the School of Public Health, Tehran University of Medical Sciences, the patient tested positive for Strongyloides stercoralis using an enzyme-linked immunosorbent assay (ELISA) kit (Novalisa, NovaTec, Germany). The infection was successfully treated with anthelmintic drugs. It is crucial to consider strongyloidiasis in patients with a history of residing in endemic areas or immigration, and testing should be conducted before initiating immunosuppressive therapy. The ELISA method is a rapid and effective diagnostic tool for detecting S. stercoralis in suspected patients, particularly before corticosteroid treatment.

Keywords

Main Subjects

References

  1. Olsen A, van Lieshout L, Marti H, Polderman T, Polman K, Steinmann P, et al. Strongyloidiasis–the most neglected of the neglected tropical diseases? Transactions of the Royal Society of Tropical Medicine and Hygiene. 2009;103(10):967-72.
  2. Schär F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides stercoralis: global distribution and risk factors. PLoS neglected tropical diseases. 2013;7(7):e2288.
  3. Nutman TB. Human infection with Strongyloides stercoralis and other related Strongyloides species. Parasitology. 2017;144(3):263-73.
  4. Sharifdini M, Mirhendi H, Ashrafi K, Hosseini M, Mohebali M, Khodadadi H, et al. Comparison of nested polymerase chain reaction and real-time polymerase chain reaction with parasitological methods for detection of Strongyloides stercoralis in human fecal samples. The American journal of tropical medicine and hygiene. 2015;93(6):1285.
  5. Muller R, Wakelin D. Worms and human disease: CABi; 2002.
  6. Mejia R, Nutman TB. Screening, prevention, and treatment for hyper_infection syndrome and disseminated infections caused by Strongyloides stercoralis. Current opinion in infectious diseases. 2012;25(4):458-63.
  7. Mendonça SC, Maria do Rosário F, Rodrigues RM, Ferreira Jr A, Costa-Cruz JM. Is there an association between positive Strongyloides stercoralis serology and diabetes mellitus? Acta Tropica. 2006;99(1):102-5.
  8. Dacal E, Saugar J, Soler T, Azcárate J, Jiménez M, Merino F, et al. Parasitological versus molecular diagnosis of strongyloidiasis in serial stool samples: how many? Journal of Helminthology. 2018;92(1):12-6.
  9. Najafi N, Soleymani E, Sarvi S, Marofi A, Nosrati A, Davoodi A. Disseminated Strongyloidiasis in an Iranian immunocompromised patient: a case report. Iranian Journal of Parasitology. 2016;11(2):279.
  10. Meamar AR, Jalallou N, Masoori L, Alipour M. Disseminated and Hyper_infection Fatal Strongyloidiasis in Two Patients on Immunosuppressive Therapy: A Case Report. Medical Laboratory Journal. 2019;13(6).
  11. Sharifdini M, Kia EB, Ashrafi K, Hosseini M, Mirhendi H, Mohebali M, et al. An analysis of clinical characteristics of Strongyloides stercoralis in 70 indigenous patients in Iran. Iranian Journal of Parasitology. 2014;9(2):155.
  12. Lai C-P, Hsu Y-H, Wang J-H, Lin C-M. Strongyloides stercoralis infection with bloody pericardial effusion in a non-immunosuppressed patient. Circulation journal. 2002;66(6):613-4.
  13. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clinical microbiology reviews. 2004;17(1):208-17.
  14. Carvalho E, Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV‐1 and Strongyloides stercoralis. Parasite immunology. 2004;26(11‐12):487-97.
Archives of Razi Institute
Volume 80, Issue 2
March and April 2025
Pages 639-642

Files

Share

How to cite

Statistics